美国炎症性肠病新近共识和指南述要

魏娟; 汪芳裕

doi:10.3969/j.issn.1671-038X.2024.08.09

美国炎症性肠病新近共识和指南述要

魏娟¹,
汪芳裕^1, ,

- 东部战区总医院南京大学医学院附属金陵医院消化内科(南京，210007)

详细信息

通讯作者: 汪芳裕，E-mail：wangfy65@nju.edu.cn

中图分类号: R259

收稿日期: 2024-05-11

刊出日期: 2024-08-15

New insights into inflammatory bowel disease management from the latest American guidelines

WEI Juan¹,
WANG Fangyu^1, ,

- Department of Gastroenterology, Jinling Hospital Affiliated to Nanjing University School of Medicine, Eastern Theater Command General Hospital, Nanjing, 210007, China

More Information

Corresponding author: WANG Fangyu, E-mail: wangfy65@nju.edu.cn

Received Date: 11 May 2024

Publish Date: 15 August 2024

摘要

摘要: 炎症性肠病(inflammatory bowel disease，IBD)是一种特发性累及胃肠道的慢性炎症性疾病，由多种病因引起，其发病机制尚未完全明了，有终生复发倾向，且缺乏特效的治疗方法，常需多学科共同诊治和关怀。随着IBD相关的分子基础研究及临床研究快速发展，新的治疗药物如生物制剂、小分子药物快速迭代更新。笔者对美国胃肠病学会近年发表的相关IBD诊治指南及共识进行扼要介绍和述评，以期为IBD的规范化诊治提供帮助。
- 炎症性肠病 /
- 溃疡性结肠炎 /
- 克罗恩病 /
- 治疗目标 /
- 生物制剂 /
- 小分子药物
Abstract: Inflammatory bowel disease(IBD) is an idiopathic chronic inflammatory disease involving the gastrointestinal tract, with many underlying causes. The etiology of IBD remains largely unknown. IBD has a tendency of lifelong recurrence, lacking of optimal treatments and requiring multi-disciplinary diagnosis and care. With the rapid development of molecular basic research and clinical research related to IBD, new therapeutic drugs such as biologics and small molecule drugs are rapidly updated. In this review, the author summarizes the current status and progress of drug therapy for IBD based on guidelines or consensus from American Gastroenterological Association recent years, in order to provide help for the standardized management of IBD in China.
- inflammatory bowel disease /
- ulcerative colitis /
- Crohn's disease /
- treating to target /
- biologics /
- small molecule drugs

HTML全文

参考文献(36)

[1]	Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413. doi: 10.14309/ajg.0000000000000152
[2]	Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis[J]. Gastroenterology, 2019, 156(3): 748-764. doi: 10.1053/j.gastro.2018.12.009
[3]	Lichtenstein GR, Loftus EV, Isaacs KL, et al. Correction: ACG clinical guideline: management of Crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113(7): 1101. doi: 10.1038/s41395-018-0120-x
[4]	Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease[J]. Gastroenterology, 2021, 160(7): 2496-2508. doi: 10.1053/j.gastro.2021.04.022
[5]	Ananthakrishnan AN, Adler J, Chachu KA, et al. AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease[J]. Gastroenterology, 2023, 165(6): 1367-1399. doi: 10.1053/j.gastro.2023.09.029
[6]	Shen B, Kochhar GS, Kariv R, et al. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium[J]. Lancet Gastroenterol Hepatol, 2021, 6(10): 826-849. doi: 10.1016/S2468-1253(21)00101-1
[7]	Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease(STRIDE): determining therapeutic goals for treat-to-target[J]. Am J Gastroenterol, 2015, 110(9): 1324-1338. doi: 10.1038/ajg.2015.233
[8]	Turner D, Ricciuto A, Lewis A, et al. STRIDE-Ⅱ: an update on the selecting therapeutic targets in inflammatory bowel disease(STRIDE)initiative of the international organization for the study of IBD(IOIBD): determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. doi: 10.1053/j.gastro.2020.12.031
[9]	Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review[J]. Clin Gastroenterol Hepatol, 2018, 16(3): 343-356. e3. doi: 10.1016/j.cgh.2017.06.016
[10]	Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis[J]. Gastroenterology, 2020, 158(5): 1450-1461. doi: 10.1053/j.gastro.2020.01.006
[11]	Ardizzone S. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis[J]. Gut, 2006, 55(1): 47-53. doi: 10.1136/gut.2005.068809
[12]	Singh S, Murad MH, Fumery M, et al. First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis[J]. Clin Gastroenterol Hepatol, 2020, 18(10): 2179-2191. e6. doi: 10.1016/j.cgh.2020.01.008
[13]	Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease[J]. Gastroenterology, 2017, 153(3): 827-834. doi: 10.1053/j.gastro.2017.07.032
[14]	Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology, 2014, 146(2): 392-400. e3. doi: 10.1053/j.gastro.2013.10.052
[15]	Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression[J]. Clin Gastroenterol Hepatol, 2007, 5(1): 103-110. doi: 10.1016/j.cgh.2006.09.033
[16]	Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial[J]. Lancet, 2012, 380(9857): 1909-1915. doi: 10.1016/S0140-6736(12)61084-8
[17]	Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis(CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(1): 15-24. doi: 10.1016/S2468-1253(16)30003-6
[18]	Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2015, 13: 330-335. e1. doi: 10.1016/j.cgh.2014.07.041
[19]	Govani SM, Waljee AK, Stidham RW, et al. Accelerateddosing of infliximab prevents colectomy within 90 days inonly half of patients with severe ulcerative colitis[J]. Gastroenterology, 2016, 150: S106.
[20]	Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials[J]. Lancet, 2022, 399(10341): 2113-2128. doi: 10.1016/S0140-6736(22)00581-5
[21]	Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study[J]. Gastroenterology, 2023, 165(6): 1443-1457. doi: 10.1053/j.gastro.2023.08.038
[22]	Feagan BG, Sandborn WJ, D'Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study[J]. Lancet, 2017, 389(10080): 1699-1709. doi: 10.1016/S0140-6736(17)30570-6
[23]	D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis[J]. N Engl J Med, 2023, 388(26): 2444-2455. doi: 10.1056/NEJMoa2207940
[24]	Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis(ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies[J]. Lancet, 2023, 401(10383): 1159-1171. doi: 10.1016/S0140-6736(23)00061-2
[25]	Shen B. Diagnosis and treatment of patients with pouchitis[J]. Drugs, 2003, 63(5): 453-461. doi: 10.2165/00003495-200363050-00002
[26]	Travis S, Silverberg MS, Danese S, et al. Vedolizumab for the Treatment of Chronic Pouchitis[J]. N Engl J Med, 2023, 388(13): 1191-1200. doi: 10.1056/NEJMoa2208450
[27]	Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases[J]. J Crohns Colitis, 2016, 10: 1385-1394. doi: 10.1093/ecco-jcc/jjw116
[28]	Van Der Sloot KW, Joshi AD, Bellavance DR, et al. Visceral adiposity, genetic susceptibility, and risk of complications among individuals with Crohn's disease[J]. Inflamm Bowel Dis, 2017, 23: 82-88. doi: 10.1097/MIB.0000000000000978
[29]	Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease[J]. Aliment Pharmacol Ther, 2006, 23: 1097-1104. doi: 10.1111/j.1365-2036.2006.02854.x
[30]	Laukoetter MG, Mennigen R, Hannig CM, et al. Intestinal cancer risk in Crohn's disease: a meta-analysis[J]. J Gastrointest Surg, 2011, 15: 576-583. doi: 10.1007/s11605-010-1402-9
[31]	Roberts RL, Gearry RB, Hollis-Moffatt JE, et al. IL23R R381Q andATG16 L1 T300A are strongly associated with crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease[J]. Am J Gastroenterol, 2007, 102: 2754-2761. doi: 10.1111/j.1572-0241.2007.01525.x
[32]	Pellise M, Lopez-Ceron M, Rodriguez de Miguel C, et al. Narrow-bandimaging as an alternative to chromoendoscopy for the detection ofdysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study[J]. Gastrointest Endosc, 2011, 74: 840-848. doi: 10.1016/j.gie.2011.05.013
[33]	Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. Ⅱ: Measures and markers of predictionto achieve, detect, and monitor intestinal healing in inflammatory boweldisease[J]. J Crohns Colitis, 2011, 5: 484-898. doi: 10.1016/j.crohns.2011.07.003
[34]	Yamamoto T, Bamba T, Umegae S, et al. The impact of early endoscopiclesions on the clinical course of patients following ileocolonic resection for Crohn's disease: a 5-year prospective cohort study[J]. United European Gastroenterol J, 2013, 1: 294-298. doi: 10.1177/2050640613495197
[35]	Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the post-operative course of Crohn's disease[J]. Gastroenterology, 1990, 99: 956-963. doi: 10.1016/0016-5085(90)90613-6
[36]	Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study[J]. Inflamm Bowel Dis, 2009, 15: 1460-1466. doi: 10.1002/ibd.20915